Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

2025-08-08 05:13:50 ET

Compugen ( CGEN ) is gearing up for several catalysts over the next few years. Its key program is the development of its potential best-in-class anti-PVRIG antibody COM701 which is being explored in the ongoing phase 1/2 MAIA-ovarian study targeting patients with relapsed platinum-sensitive ovarian cancer [PSOC]. The reason why I bring up this program is because the company started dosing patients in sub-study 1 targeting these relapsed PSOC patients in July of 2025. It is expected that an interim analysis of this particular study cohort will be released in the 2nd half of 2026....

Read the full article on Seeking Alpha

For further details see: